Because it causes tissue damage and tissue death in the legs, feet, and toes, PAD is implicated in 150,000 lower-limb ...
The ZENITH trial showed sotatercept significantly reduced death, transplant, or hospitalization risk in advanced PAH, leading ...
Until now, people with PAD haven’t had many good treatment options. There is one drug, cilostazol, that can help people walk ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
Schizophrenia spectrum disorders significantly increase cardiovascular and metabolic disease risks, partly due to antipsychotic-induced weight gain and glucose dysregulation.
MedPage Today on MSN
GLP-1 Drugs Linked to Lower Epilepsy Risk in Diabetes Patients
GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Epilepsy is an ...
I know therapists use music to get through to people with Alzheimer’s disease who don’t really connect with anything else anymore. I just saw on the news that ...
Standard workplace drug tests are unlikely to detect Ozempic, since semaglutide controlled substances. While routine urine tests usually don’t reveal Ozempic, specialized blood tests can detect the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results